pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Apr 28·1 min read
save

EPA proposes first rule to flag microplastics and pharmaceuticals in drinking water, alongside $144 million ARPA-H study program

Apr 28, 2026·read at STAT ↗RegulatoryNeutral

The Environmental Protection Agency announced a proposed rule that would formally label microplastics and pharmaceutical residues in drinking water as contaminants that merit federal study and tracking.

The Department of Health and Human Services also unveiled a $144 million ARPA‑H initiative aimed at standardizing how microplastics are measured in the human body, investigating potential health impacts, and identifying ways to reduce exposure.

The proposal does not establish any legal limits for these substances in water supplies, nor does it require utilities to remove them. Even if finalized, additional regulatory steps would be needed before binding standards take effect.

The authors note that the bipartisan moment offers a chance for substantive action, but they caution that the effort could stall without further concrete measures.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “Opinion: It’s time to seize the rare bipartisan opening to address microplastics”

read at STAT ↗
1,242 words · retrieved Apr 30
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Ultragenyx Pharmaceutical Inc.4
drugs
STERILE WATER8
topics
Rare Disease4Hepatology3Endocrinology & MetabolismGastroenterologyHematologyOphthalmology

related stories

  • Jun 2910 clinical trials to watch in the second half of 2026BioPharma Dive
  • Dec 22Fierce Biotech Fundraising Tracker '26: Estuary channels $93M series A; OMass obtains $310MFierce Biotech
  • 2d agoNext-gen RNAi drugmaker City prices $200M IPOBioPharma Dive
  • 3d agoGSK laying off 1.2K+ in BelgiumBioSpace
  • 5d agoMerck KGaA spinout iOnctura touts PI3K delta inhibitor in metastatic eye cancerFierce Biotech